BGLCNasdaqServices-Medical LaboratoriesFiscal year ends December 31
BioNexus Gene Lab Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$1.23+0.03 (+2.23%)
Close on Oct 19, 2026
- Market cap
- $2.97M
- P/E (TTM)
- –
- Dividend yield
- –
BioNexus Gene Lab Corp revenue by segment
By business segment
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Maldives | $360.35K | $499.92K | $680.99K | $876.95K | $755.96K | $715.87K | $762.14K | 11.5% | -52.3% |
| Sri Lanka | $197.17K | $306.54K | $452.64K | $592.57K | $527.99K | $488.94K | $459.00K | 6.3% | -62.7% |
| Singapore | $108.91K | $206.53K | $240.76K | $271.62K | $602.91K | $536.02K | $572.03K | 3.5% | -81.9% |
| Malaysia | – | – | – | $7.63M | $7.60M | $7.40M | $7.46M | – | – |
| INDONESIA | – | – | $114.87K | – | – | – | $138.30K | – | – |
| Myanmar | – | $5.85M | $5.83M | $9.18M | $9.18M | $9.20M | $7.46M | – | – |
From the segment and revenue-disaggregation notes of BioNexus Gene Lab's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.